← All Sponsors
SPONSOR

Gilead Sciences

Total Trials
6
Recruiting
6
Phases
Phase 2, Phase 3, Phase 1, Phase 2, Phase 3
Conditions studied: HIV-1-infectionMetastatic Urothelial CancerTriple Negative Breast CancerLung CancerAdvanced or Metastatic Non-Small-Cell Lung CancerResectable Non-Small-Cell Lung CancerHIV Pre-exposure Prophylaxis
NCT06532656 Phase 2, Phase 3
Recruiting

Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

HIV-1-infection
United States, Argentina, Italy View Trial →
NCT07055451 Phase 1
Recruiting

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV

HIV-1-infection
United States, South Africa View Trial →
NCT03547973 Phase 2
Recruiting

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Metastatic Urothelial Cancer
United States, France, Germany View Trial →
NCT05633654 Phase 3
Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Triple Negative Breast Cancer
United States, Australia, France View Trial →
NCT05633667 Phase 2
Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer

Lung Cancer
United States, Brazil, Hong Kong View Trial →
NCT07047716 Phase 3
Recruiting

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

HIV Pre-exposure Prophylaxis
United States View Trial →